NY-EMENDO-BIO
17.5.2022 22:17:09 CEST | Business Wire | Press release
Emendo Biotherapeutics presented the results of its next generation CRISPR-based gene editing approaches for several indications in an oral presentation and three posters at the 25th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) held May 16-19, 2022, in Washington, D.C.
Emendo presented pre-clinical data for the treatment of ELANE -related Severe Congenital Neutropenia using an allele-specific editing approach, demonstrating the power of Emendo’s dual technology platforms that enable the development of a highly specific editing composition that demonstrates no off-targets and complete allele specificity. Significantly, the lack of off-target achieved by Emendo’s engineered and optimized OMNI nuclease also eliminated any translocations. Edited patient derived CD34+ cells differentiated normally into neutrophils both in-vitro and in-vivo , showing full engraftment and reconstitution of all blood lineages, as required for the desired therapeutic effect.
“ELANE -based Severe Congenital Neutropenia, Emendo’s lead indication, is a devastating disease affecting pediatric patients that until now has been incurable,” said David Baram, Ph.D., President & CEO of Emendo Biotherapeutics. “We are excited by the potentially curative treatment developed by our team and were pleased to present our pre-clinical results for this program and other diverse applications of our dual gene editing technology platforms at this year’s ASGCT meeting. And of course, we look forward to the discussion generated by our discoveries around Type II CRISPR nuclease classifications that promise to be ground-breaking in the field.”
Senior members of the Emendo Biotherapeutics R&D team including Chief Technology Officer Lior Izhar, Ph.D. and Executive Vice-President Research & Development Rafi Emmanuel, Ph.D. presented Emendo’s research on-site at the conference.
Session Presentation
Title: A Novel Engineered CRISPR-Associated Nuclease Accurately Removes ELANE Mutated Allele and Shifts HSC Differentiation Towards Neutrophils in Severe Congenital Neutropenia
Session Title: Gene Therapy for Immunologic Diseases
Session Date/Time: Tuesday May 17, 2022 3:45 PM - 5:30 PM
Presentation Time: 3:45pm - 4:00pm
Room: Room 202
Final abstract number: 482
Poster Presentations
Title: A Unique CRISPR-Based Nuclease with a Non-NGG PAM Efficiently Targets Multiple Exclusive Genomic Sites for Immuno-Oncology Based Therapy
Session Title: Cancer - Targeted Gene and Cell Therapy I
Session Date/Time: Monday May 16, 2022 5:30 PM - 6:30 PM
Poster Board Number: M-215
Room: Hall D
Final abstract number: 334
Title: CRISPR-Based Gene Editing Enhances LDLR Expression and Boosts LDL-C Uptake in Familial Hypercholesterolemia
Session Title: Metabolic, Storage, Endocrine, Liver and Gastrointestinal Diseases II
Session Date/Time: Wednesday May 18, 2022 5:30 PM - 6:30 PM
Poster Board Number: W-125
Room: Hall D
Final abstract number: 999
Title: Challenges and Inconsistencies in Type II CRISPR-Associated Nuclease Subtype Classification
Session Title: Gene Targeting and Gene Correction II
Session Date/Time: Tuesday May 17, 2022 5:30 PM - 6:30 PM
Poster Board Number: Tu-61
Room: Hall D
Final abstract number: 556
About Emendo Biotherapeutics
Emendo Biotherapeutics, a subsidiary of AnGes, Inc., is a next generation CRISPR gene editing company leveraging dual proprietary technology platforms to enable high precision gene editing throughout the genome. Emendo’s novel nuclease discovery platform broadens the targetable range of the genome while its target-specific optimization platform enables highly precise editing, including allele specific editing, while maintaining high efficiencies. The capabilities of the OMNI technology platforms, along with deep expertise in genomic medicine, protein engineering and therapeutic development, provide Emendo with a unique advantage when addressing indications within hematology, oncology, ophthalmology and other disease areas. For more information please visit www.emendobio.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220517006030/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Visa Renews Partnership Across Red Bull Formula One Teams19.2.2026 15:00:00 CET | Press release
Long‑term renewal deepens Visa’s presence across Red Bull F1 Teams with enhanced branding, fan access and client experiences Renewed partnership to expand support of Oracle Red Bull Racing and Visa Cash App Racing Bulls Visa (NYSE: V) today announced a multi‑year renewal and expansion of its global partnership with Red Bull F1 Team’s Oracle Red Bull Racing and Visa Cash App Racing Bulls. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260219542270/en/ Building on the groundbreaking partnership launched in 2024, the renewed agreement reinforces Visa’s commitment to one of the world’s fastest‑growing sports, while introducing significant new branding rights, enhanced hospitality assets and immersive experiential opportunities across both teams. Visa will also continue as a Title Partner of both Visa Cash App Racing Bulls Formula One Team and its F1 Academy Programme, further strengthening Visa’s presence on and off the grid. “T
Project B Taps Fashion Industry Veteran William Kim as Chief Lifestyle Officer19.2.2026 15:00:00 CET | Press release
Global basketball platform merges elite sport with fashion, design, and culture Project B, an elite global women’s and men’s basketball grand prix built for a new generation of athletes and fans, today announced the appointment of William Kim as Chief Lifestyle Officer. In this strategic role, Kim will lead Project B’s premium lifestyle business across merchandise, brand collaborations, and cultural partnerships as Project B expands across Europe, Asia, and the Americas to create the most premium cultural platform in global sport. “We are building a model designed for 2030 and beyond,” said Kim. “It starts with creating exceptional products. We’re sourcing the highest quality natural fibers for every moment in an athlete’s day and offering those same collections to the broader fan community. From design to supply chain to final consumer experience, we are operating with the same discipline and control as a luxury house, overseeing product, distribution, and brand experience holisticall
Aeris Integrates with Palo Alto Networks to Secure the Wireless IoT Blind Spot with Agentless, Global SASE19.2.2026 15:00:00 CET | Press release
Aeris, a leader in wireless management platforms, security services and connected vehicle programs, today announced it has completed its product integration with Palo Alto Networks Prisma SASE 5G and joined an extensive ecosystem of Palo Alto Networks Technology Partners to deliver intelligent and interoperable solutions that enable joint customers with turnkey integrations that help them more easily and confidently secure their digital transformation journey. The integration combines Aeris IoT Watchtower™ with Palo Alto Networks Prisma SASE 5G to transform how enterprises protect wireless IoT deployments, providing a single point of control to extend security to the wireless IoT edge. The integration provides Layer 7 security features, including Deep Packet Inspection (DPI) and Data Loss Prevention (DLP), across a global footprint. By validating interoperability between these platforms, Aeris and Palo Alto Networks allow businesses to reduce their attack surface and bring previously i
Fosway 9-Grid™ Analysis Identifies O.C. Tanner as Strategic Leader in the Talent & People Success Market19.2.2026 15:00:00 CET | Press release
O.C. Tanner, the global leader in employee recognition and culture solutions, is honored to be recognized once again as a Strategic Leader in the latest Fosway 9-Grid™ for Talent & People Success. This top industry placement from Fosway Group, Europe’s leading HR and talent analyst, reaffirms O.C. Tanner’s ongoing commitment to innovating employee engagement and workplace culture. Fosway’s independent analysis positions vendors based on performance, potential, market presence, total cost of ownership, and trajectory, helping HR leaders make informed decisions about workplace solutions. O.C. Tanner’s recognition reflects both the strength of its Culture Cloud® platform and its ability to support complex, enterprise-level needs with meaningful outcomes. “Being named a Strategic Leader by Fosway is a powerful validation of the impact our team is delivering for organizations around the world,” said Scott Sperry, President and CEO of O.C. Tanner. “Today’s talent environment demands culture-
Calvin Klein Fragrances announces ROSALÍA as the face of new euphoria elixirs19.2.2026 14:30:00 CET | Press release
Campaign fronted by the global superstar and brand ambassador explores the distinct universes of the three new parfums Calvin Klein, Inc., part of PVH Corp. [NYSE: PVH], and Calvin Klein Fragrances, a division of Coty Inc. [NYSE: COTY], today unveil GRAMMY® Award-winning singer-songwriter ROSALÍA as the face of euphoria elixirs, a new collection of three distinct parfum intense creations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260219549836/en/ Calvin Klein Fragrances announces ROSALÍA as the face of new euphoria elixirs. A daring new chapter of the iconic euphoria franchise, euphoria elixirs are a sensorial exploration of confidence, pleasure and sensuality. Embodied by global icon and Calvin Klein ambassador ROSALÍA, the campaign fuses movement and vivid color into a captivating exploration of freedom without limits. Known for her genre-defying sound and commanding visual artistry, ROSALÍA channels the fragrances’ m
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom